Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
16.57
+0.01 (0.03%)
May 5, 2026, 12:38 PM EDT - Market open
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.19T JPY in the quarter ending December 31, 2025, with 4.16% growth. This brings the company's revenue in the last twelve months to 4.46T, down -1.13% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.46T JPY
Revenue Growth
-1.13%
P/S Ratio
1.85
Revenue / Employee
94,080,287 JPY
Employees
47,455
Market Cap
52.81B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.20B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.35B |
| Haleon | 14.85B |
| Viatris | 14.30B |
| Zoetis | 9.47B |
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Neurocrine Biosciences | 2.86B |
TAK News
- 1 day ago - Takeda's immune disease drug meets main goal of mid-to-late stage trial - Reuters
- 1 day ago - Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) - Business Wire
- 4 weeks ago - Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why - Benzinga
- 5 weeks ago - Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care - Business Wire
- 6 weeks ago - TrumpRx lists many medicines at prices higher than paid in UK - Reuters
- 2 months ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 2 months ago - Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis - Business Wire
- 3 months ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire